Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

47P - Quality of life after extended pelvic exenterations

Date

17 Jun 2022

Session

Poster Display session

Topics

Surgical Oncology;  Psychosocial Aspects of Cancer

Tumour Site

Ovarian Cancer;  Endometrial Cancer;  Cervical Cancer;  Vulvar and Vaginal Cancers

Presenters

David Cibula

Citation

Annals of Oncology (2022) 33 (suppl_5): S402-S403. 10.1016/annonc/annonc919

Authors

D. Cibula1, S. Lednicky1, E. Höschlová2, J. Slama1, M. Wiesnerová3, P. Mitáš4, Z. Matejovský5, L. Dostálek1, M. Borcinová1

Author affiliations

  • 1 General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague/CZ
  • 2 Faculty of Arts, Charles University in Prague, Czech Republic, Prague/CZ
  • 3 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, Brno/CZ
  • 4 Second surgical clinic – cardiovascular surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague/CZ
  • 5 FN Bulovka - University Hospital Bulovka, Prague/CZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 47P

Background

While traditional pelvic exenterations (PE) represent a potentially curative treatment for recurrent tumours localized centrally in the pelvis, new surgical techniques have been developed recently to enable a complete resection even in tumours invading into the pelvic side wall. Extended pelvic exenterations (EPE) include resection of internal, external, or common iliac vessels, pelvic side-wall muscles, large pelvic nerves, or pelvic bones. EPE are currently performed only in a few institutions and data on treatment morbidity are not available. The aim of the study was to compare health-related quality of life (QoL) and oncological outcome after PE and EPE.

Methods

Data from 72 patients with cervical (36), vulvar (19), endometrial (14) and low-grade ovarian (5) cancer who underwent PE (42) or EPE (32) for persistent (20%) or recurrent (80%) disease between 2014 to 2019 at a single tertiary centre were analysed. Quality of life was evaluated in surviving patients using EORTC QLQ-C30, EORTC CX-24, and QOLPEX questionnaire developed specifically for patients after extensive pelvic procedures.

Results

Median overall and disease-specific survival reached in the whole cohort 45 and 49 months, without significant differences between PE and EPE groups (P >0.999). We did not observe any difference in post-surgical complication types or frequency between the groups. Thirty-one survivors participated in the QoL assessment (20 PE, 11 EPE) and no significant differences were found in global health status (P=0.951) or in any of the functional scales. The groups were not differing in therapy satisfaction (P=0.502), and both expressed similar willingness to potentially undergo treatment again (P=0.317) (Table). Table: 47P

EORTC QLQ 30, EORTC QLQ-CX24 – Main results

Pelvic exenteration Extended pelvic exenteration
Valid (missing) Mean (SD) Valid (missing) Mean (SD) P-value
Functional scales (higher value = better functioning)
Global health status 20 62.9 (19.75) 11 64.5 (21.36) 0.951
Physical functioning 20 67.2 (23.92) 11 73.0 (19.62) 0.583
Role functioning 20 57.8 (40.28) 11 60.9 (31.84) 0.951
Emotional functioning 20 75.2 (20.64) 11 81.2 (18.34) 0.427
Cognitive functioning 20 87.8 (16.78) 11 82.3 (11.60) 0.157
Therapy assessment (higher value = higher satisfaction)
Would undergo again 20 83.8 (28.42) 11 72.7 (28.40) 0.317
Therapy satisfaction 20 90.0 (18.85) 11 86.36 (17.19) 0.502

SD, standard deviation.

Conclusions

EPE are associated with similar post-treatment QoL and survival as traditional PE. These procedures represent potentially curative treatment option for patients with persistent or recurrent pelvic cancer invading into pelvic wall structures without further compromising QoL.

Legal entity responsible for the study

The authors.

Funding

Charles University in Prague (UNCE 204065 and PROGRES Q28/LF1).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.